Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 745-65-3 Chemical Structure| 745-65-3

Structure of Prostaglandin E1
CAS No.: 745-65-3

Chemical Structure| 745-65-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Alprostadil is an analog of prostaglandin which is prostaglandin E1 agonist with vasodilatory properties and can be used to treat erectile dysfunction.

Synonyms: PGE1; Alprostadil; Liprostin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Prostaglandin E1

CAS No. :745-65-3
Formula : C20H34O5
M.W : 354.48
SMILES Code : O=C(CCCCCC[C@@H]1[C@H]([C@@H](CC1=O)O)/C=C/[C@H](CCCCC)O)O
Synonyms :
PGE1; Alprostadil; Liprostin
MDL No. :MFCD00077860
InChI Key :GMVPRGQOIOIIMI-DWKJAMRDSA-N
Pubchem ID :5280723

Safety of Prostaglandin E1

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Prostaglandin E1

GPCR

Isoform Comparison

Biological Activity

Description
Prostaglandin E1 (Alprostadil) is a ligand for prostanoid receptors, exhibiting Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM, and 36 nM for mouse EP3, EP4, EP2, IP, and EP1 receptors respectively. It induces vasodilation and inhibits platelet aggregation, being researched as a vasodilator for peripheral vascular diseases[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
H9c2 cells 0.5 µM 12 hours hypoxia followed by 12 hours reoxygenation To investigate the effects of PGE1 on the H/R model, results showed that PGE1 treatment significantly reduced apoptosis in H9c2 cells, inhibited mPTP opening, and decreased cytochrome c and cleaved caspase-3 expression. PMC7723157
Mesenchymal stem cells 10 ng/mL 24 hours PGE1 reduces MSC apoptosis and increases CXCR4 expression, MSC migration, and VEGF secretion by activating the HIF-1α pathway PMC9288720
Human umbilical vein endothelial cells (HUVECs) 0.25, 0.50, 1.00 µM 24 hours To investigate the protective effects of PGE1 against H2O2-induced oxidative damage. PGE1 markedly restored the viability of HUVECs under oxidative stress, scavenged intracellular reactive oxygen species induced by H2O2, suppressed the production of lipid peroxides such as MDA, restored the activities of endogenous antioxidants including SOD and GSH-Px, and inhibited cell apoptosis. Additionally, PGE1 significantly increased NO content, eNOS protein, and mRNA expression. PMC4007667
Mouse trigeminal ganglion neurons 100 nM 3 minutes To investigate the effect of PGE1 on Ih current, results showed that PGE1 significantly enhanced the amplitude of Ih current PMC8706703
PTEN-knockdown PASMCs 100 nM 30 minutes to 24 hours PGE1 induced pCREB expression at 30 min, increased PTEN expression at 6 h, and decreased pAKT levels from 6 to 24 h. PMC5577102
HK-2 cells 0.1 –100 µM 48 hours To evaluate the effect of PGE1 on HK-2 cell viability under high glucose conditions, results showed PGE1 significantly enhanced cell viability PMC7471471
K562 cells 10 μM 6 hours Repressed AP-1 factors expression, simulating the effect of Tcf1/Lef1 deficiency PMC5678929
Primary cardiomyocytes 2.0 μM 6 hours hypoxia followed by 6 hours reoxygenation PGE1 protected primary cardiomyocytes against H/R-induced injuries, increased the viability of H/R-induced primary cardiomyocytes, and decreased LDH levels in a dose-dependent manner. PMC6923339
Rat H9C2 cells 0.5, 1.0, and 2.0 μM 6 hours hypoxia followed by 6 hours reoxygenation PGE1 significantly diminished the cell cytotoxicity and apoptosis induced by the 6H/6R regimen, and also decreased expression of IL-2, IL-6, P-p65, TNF-α, and cleaved-caspase-3. In addition, PGE1 up-regulated miR-21-5p expression and reduced the apoptosis ability of H/R-injured rat cardiomyocytes by affecting the miR-21-5p/FASLG axis. PMC6923339

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CML model Intraperitoneal injection 2.5-5 mg/kg Once daily for the duration of treatment Significantly reduced the number of leukemic stem cells, prolonged survival, and showed synergistic effects when combined with imatinib PMC5678929
Wistar rats Pulmonary arterial hypertension model Tail vein injection 10 ng/mL Single injection After transplantation of PGE1-preconditioned MSCs, the pulmonary artery systolic pressure, mean pulmonary artery pressure, right ventricular hypertrophy index, %WT, and %WA decreased in rats with PAH, showing better therapeutic effects than non-preconditioned MSCs PMC9288720
Wistar rats Hypoperfused rat liver model Perfusion 100 μg/liter 20 min pretreatment followed by 25% low flow perfusion Prostaglandin E1 significantly attenuated hypoperfusion-induced early reductive stress and mitochondrial dysfunction, and diminished subsequent oxidative injury and cell death PMC293748
Wistar rats Diabetic kidney disease model Intravenous injection 10 µg/kg Once daily for 10 consecutive days To evaluate the effect of PGE1 on kidney injury in diabetic kidney disease rats, results showed PGE1 significantly reduced proteinuria and renal tubular apoptosis PMC7471471
Sprague-Dawley rats Permanent middle cerebral artery occlusion model Intravenous injection 22.6 nmol/kg or 45.2 nmol/kg Single administration To examine the effects of a mixed formulation composed of prostaglandin E1 and lithium (PGE1+Li mixture) on brain damage after cerebral ischemia. The results showed that the mixture significantly reduced infarct volume and neurological deficits, and upregulated cytoprotective HSP70, GRP78, HSP60, and Bcl-2 protein levels, while decreasing p53 expression. PMC4002767
Wistar P7 rats Neonatal ischemia-reperfusion model Intraperitoneal injection 20 µg/kg Every 5 minutes for 4 times, lasting 50 minutes To evaluate whether prostaglandin E1 improves collateral recruitment and brain damage after ischemia in neonatal rats. Results showed that prostaglandin E1 delayed and improved ipsilateral reperfusion by decreasing thromboxane A synthase-1 gene expression, reducing the density of reactive astrocytes and lesion volume. PMC6213314
Sprague-Dawley rats Monocrotaline-induced pulmonary arterial hypertension (PAH) model Intraperitoneal injection 5 mg/kg Once daily for 3 weeks PGE1 prevented pulmonary arterial remodeling and improved hemodynamics via the induced expression of PTEN. PMC5577102
C57BL/6 mice Orofacial pain model Subcutaneous injection 10 ng/10 μL and 20 ng/10 μL Single injection, observed for 90 minutes To investigate PGE1-induced orofacial pain behavior, results showed that PGE1 induced mechanical allodynia in a dose-dependent manner PMC8706703
Wistar rats Asphyxia-induced cardiac arrest model Intravenous injection 1 µg/kg Single dose To evaluate the protective effects of PGE1 on post-cardiac arrest myocardial dysfunction, results showed that PGE1 significantly increased ejection fraction and cardiac output, improved survival rate, and reduced cardiomyocyte apoptosis. PMC7723157

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04312555 Critical Limb Ischemia PHASE4 UNKNOWN 2021-10-01 -
NCT00610051 Heart Failure PHASE3 NOT_YET_RECRUITING 2025-12-26 Medical university Vienna, Vie... More >>nna, Austria Less <<
NCT01776320 Erectile Dysfunction PHASE4 WITHDRAWN 2025-12-15 St. Joseph's Health Care Londo... More >>n, London, Ontario, N6A 4V2, Canada Less <<
NCT04496050 Pyloric Stenosis;Acquired|Cong... More >>enital Heart Disease Less << UNKNOWN 2020-11-30 Hacettepe University, Ankara, ... More >>Turkey Less <<
NCT03027219 Diabetes COMPLETED 2018-11-29 Asan Medical Center, Seoul, 05... More >>505, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.82mL

0.56mL

0.28mL

14.11mL

2.82mL

1.41mL

28.21mL

5.64mL

2.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories